Prelude announces strategic pipeline progress and updates, including its partnership with abcellera, and reports third quarter financial results

Prioritization of its first-in-class smarca2 degrader and potentially best-in-class cdk9 inhibitor programs for continued clinical development enters partnership with abcellera to develop a portfolio of precision adcs with first program being a smarca degrader-antibody conjugate cash runway into 2026 with $230.5 million of cash, cash equivalents and marketable securities wilmington, del., nov. 01, 2023 (globe newswire) -- prelude therapeutics incorporated (prelude) (nasdaq: prld), a clinical-stage precision oncology company, today provides strategic pipeline updates and reports third quarter financial results.
PRLD Ratings Summary
PRLD Quant Ranking